Metrizamide

Summary

Metrizamide (CHEMBL462394) is an approved small molecule (ATC V08AB01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB01
• Chemistry: 789.1 Da · C18H22I3N3O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL462394
Name	Metrizamide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	443944
ATC	V08AB01
Molecular formula	C18H22I3N3O8
Molecular weight	789.1
InChIKey	BAQCROVBDNBEEB-UBYUBLNFSA-N

SMILES: CC(=O)NC1=C(C(=C(C(=C1I)C(=O)N[C@@H]2[C@H]([C@@H]([C@H](OC2O)CO)O)O)I)N(C)C(=O)C)I

IUPAC name: 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide

Also known as: Amipaque, Metrizamida, Metrizamide, Telebrix 300, WIN 39103, WIN-39103, METRIZAMIDE, SID144204170, metrizamide

Patent coverage: 1,770 distinct patent families (6,449 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,441 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).